Price movement over the last 24 hours
iShares Core US Aggregate Bond ETF vs Baxter International Inc — how do they compare? iShares Core US Aggregate Bond ETF trades at $98.05, while Baxter International Inc trades at $22 (market cap $11.81B). The key difference: Baxter International Inc pays a 0.87% dividend while iShares Core US Aggregate Bond ETF pays none, and Baxter International Inc is trading nearer its 52-week high, iShares Core US Aggregate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AGG | BAX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $101.40 | $30.66 |
52-Week Low | $97.63 | $15.80 |
Market Cap | — | $11.81B |
Enterprise Value | — | $19.48B |
Dividend Yield | — | 0.87% |
Signals from Pluang's Aura AI — not financial advice
AGG trades at $98.65, up 0.04% on the day, with technical indicators showing a bearish trend from moving averages but a neutral signal from oscillators. The stock faces resistance at $99 and support at $98. Recent corporate actions include scheduled dividends for May and June 2026. Financial ratios are unavailable in the provided data, limiting fundamental analysis.
The outlook remains cautious due to the bearish technical bias and lack of current financial metrics. Key risks include market volatility and interest rate uncertainty. Investors should await updated earnings reports for a clearer fundamental picture before considering positions.
Baxter International (BAX) trades at $22.86, up 0.93% today, near the consensus price target of $22.67. The stock shows a bullish technical trend with recent earnings beats in Q1 2026, though profitability remains weak with a negative net income margin of -9.7% and ROE of -16.73%. Cash flow trends indicate operational challenges, with net cash flow negative in recent periods. Recent news highlights sustainability initiatives and strategic partnerships, supporting a turnaround narrative amid ongoing financial restructuring.
Outlook: BAX presents a mixed opportunity with analyst consensus leaning Hold (52.77%) amid valuation concerns (P/E 87.85) and persistent losses. Key risks include high debt, margin pressure, and execution hurdles in stabilizing the business. Upside potential exists if operational improvements and AI integration drive sustained earnings recovery, but investors should weigh the high volatility and competitive pressures in the medtech sector.
Trailing returns across standard periods
AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.
Read more on AGG →Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →